[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
Hans-Christoph
HC
Diener
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D002544:Cerebral Infarction / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D004311:Double-Blind Method; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007279:Injections, Subcutaneous; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000401:mortality / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D015996:Survival Rate; D020246:Venous Thrombosis / Q000401:mortality / Q000517:prevention & control*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; C403769:certoparin